Avadel Pharma (NASDAQ: AVDL) reported Q3 EPS of ($0.03), $0.05 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $50.03 million versus the consensus estimate of $48.44 million.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.